Softgel Healthcare Private Limited
Softgel Healthcare Private Limited is a Private Non-govt company company incorporated in 2003 and based in Tamil Nadu, India. Softgel Healthcare Private Limited operates in Chemical substances used in the manufacture of anti-biotic, manufacturing (NIC 24231) with authorized capital of ₹30.00 Cr and paid-up capital of ₹27.77 Cr. For 2023-24, the company reported revenue of ₹230.37 Cr and profit after tax of ₹31.12 Cr. The board has 3 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Quick facts
Directors
3 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +13d | filed |
| MGT-7 | FY2024-25 | 23 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +10d | filed |
| MGT-7 | FY2023-24 | 25 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 24 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Softgel Healthcare Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 878207300 | Kotak Mahindra Bank Ltd(Bank) | ₹16.01 Cr | 12 Mar 2023 | Satisfied |
| 899592763 | Kotak Mahindra Bank Ltd(Bank) | ₹10.11 Cr | 19 Sep 2021 | Open |
| 987690265 | ICICI Bank Ltd(Bank) | ₹1.48 Cr | 19 Sep 2020 | Open |
| 991934163 | Axis Bank Ltd(Bank) | ₹13.07 Cr | 27 Jan 2021 | Open |
Charge IDs, lenders & amounts for Softgel Healthcare Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2021-22 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2018-19 | — | ||||
| 2017-18 | — |
Detailed Financials
4 FYs| Line item | 2023-24 | 2021-22 | 2020-21 | 2019-20 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | -2.0% | +1.0% | +87.0% | |
| Profit after Tax2023-24 | -47.0% | +66.0% | +50.0% | |
| Net Worth2023-24 | +59.0% | +77.0% | +80.0% |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2017-18 | +10.30% | — | +22.37% | +8.80% | — | |||
| 2018-19 | +9.25% | +22.78% | +19.77% | +9.79% | — | |||
| 2019-20 | +11.99% | +31.82% | +25.24% | +12.99% | — | |||
| 2020-21 | +14.89% | -0.34% | +28.23% | +14.66% | — | |||
| 2021-22 | +19.09% | +39.39% | +33.53% | +21.20% | — | |||
| 2023-24 | +13.51% | -8.24% | +14.08% | +9.22% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 1,85,01,789 | 86.81% |
| Institutional Investors | 2 | 7,76,409 | 3.64% |
| Public & Others | 11 | 20,35,151 | 9.55% |
Promoter, institutional & public holding for Softgel Healthcare Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
5 peersTop 10 in Chemical substances used in the manufacture of anti-biotic, manufacturing
by healthView all ›Events & timeline
4External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.